NCT00112216View on ClinicalTrials.gov

Immunotherapy of Melanoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Melanoma
Interventions
BIOLOGICAL

Melan-A analog peptide

BIOLOGICAL

FluMa peptide

BIOLOGICAL

Mage-A10 peptide

BIOLOGICAL

SB AS-2 adjuvant

BIOLOGICAL

Montanide adjuvant

Trial Locations (1)

1011

Ludwig Institute for Cancer Research + Multidisciplinary Oncology Center at the Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT00112216 - Immunotherapy of Melanoma Patients | Biotech Hunter | Biotech Hunter